A Pilot Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Gradalis
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 04 May 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.